Press release
Metastatic Castration-Resistant Prostate Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZ
Metastatic Castration-Resistant Prostate Cancer Pipeline Insights
Metastatic Castration-Resistant Prostate Cancer Overview:
Prostate cancer (PCa) is one of the most common cancers globally and the third leading cause of cancer-related deaths among men in the United States. Most men diagnosed with PCa initially present with localized disease and undergo treatments such as radical prostatectomy and/or radiation therapy, often followed by androgen deprivation therapy (ADT). Depending on the cancer's grade, a portion of these patients may develop castration-resistant prostate cancer (CRPC) within 10 years. CRPC was once referred to as "hormone-refractory prostate cancer" or "androgen-independent prostate cancer." However, these cancers continue to depend on hormones for androgen receptor (AR) activation despite the ineffectiveness of castration treatments like ADT.
Request for a detailed insights report on Metastatic Castration-Resistant Prostate Cancer pipeline insights @ https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Castration-Resistant Prostate Cancer Therapeutics Market.
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) showed a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.
Also in September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
In July 2024, the ARANOTE trial demonstrated that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for mCRPC.
In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 combined with Abiraterone for mCRPC.
In May 2024, Fusion Pharmaceuticals launched the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
In April 2024, Astellas Pharma obtained European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
In April 2024, FibroGen reported positive Phase 1 trial results for FG-3246 in mCRPC.
Key Metastatic Castration-Resistant Prostate Cancer companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others are evaluating new drugs for Metastatic Castration-Resistant Prostate Cancer to improve the treatment landscape.
Promising Metastatic Castration-Resistant Prostate Cancer pipeline therapies in various stages of development include SRF617, Rucaparib, HP518, and others.
Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Metastatic Castration-Resistant Prostate Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Castration-Resistant Prostate Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Castration-Resistant Prostate Cancer market.
Download our free sample page report on Metastatic Castration-Resistant Prostate Cancer pipeline insights @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs
SRF617: Surface Oncology
Rucaparib: Clovis Oncology
HP518: Hinova Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer Companies
Over 75 key companies are actively developing therapies for metastatic castration-resistant prostate cancer (mCRPC). Among these, Clovis Oncology is one of the companies with drug candidates for mCRPC in the most advanced stage, namely Phase III.
DelveInsight's report covers around 75+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Metastatic Castration-Resistant Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Castration-Resistant Prostate Cancer Therapies and Key Companies: Metastatic Castration-Resistant Prostate Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutic Assessment
• Metastatic Castration-Resistant Prostate Cancer Assessment by Product Type
• Metastatic Castration-Resistant Prostate Cancer By Stage
• Metastatic Castration-Resistant Prostate Cancer Assessment by Route of Administration
• Metastatic Castration-Resistant Prostate Cancer Assessment by Molecule Type
Download Metastatic Castration-Resistant Prostate Cancer Sample report to know in detail about the Metastatic Castration-Resistant Prostate Cancer treatment market @ Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Metastatic Castration-Resistant Prostate Cancer Current Treatment Patterns
4. Metastatic Castration-Resistant Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Castration-Resistant Prostate Cancer Late-Stage Products (Phase-III)
7. Metastatic Castration-Resistant Prostate Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Castration-Resistant Prostate Cancer Discontinued Products
13. Metastatic Castration-Resistant Prostate Cancer Product Profiles
14. Metastatic Castration-Resistant Prostate Cancer Key Companies
15. Metastatic Castration-Resistant Prostate Cancer Key Products
16. Dormant and Discontinued Products
17. Metastatic Castration-Resistant Prostate Cancer Unmet Needs
18. Metastatic Castration-Resistant Prostate Cancer Future Perspectives
19. Metastatic Castration-Resistant Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Metastatic Castration-Resistant Prostate Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZ here
News-ID: 3847186 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
